Disease · MONDO_0009692

primary myelofibrosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. primary myelofibrosis. Diseases, record MONDO_0009692. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009692

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: primary myelofibrosis; Open Targets
Open Targets ID: MONDO_0009692; Open Targets
Other names: AMM, Agnogenic myeloid metaplasia, CIMF, aleukemic myelosis, bone marrow fibrosis, chronic idiopathic myelofibrosis, idiopathic bone marrow fibrosis, idiopathic myelofibrosis, megakaryocytic myelosclerosis, myelofibrosis with myeloid metaplasia, myelofibrosis with myeloid metaplasia, somatic, myelofibrosis, somatic, myelosclerosis, myelosclerosis with myeloid metaplasia, osteomyelofibrosis; Open Targets
Disease Ontology: DOID:4971; Disease Ontology
MeSH: D055728; MeSH
NCI Thesaurus: C2862; NCI Thesaurus
Orphanet: ORPHA:824; Orphanet
Highest stage of its drugs: Approval, for 5 of its 63 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs63

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FEDRATINIB	CHEMBL1287853	Small molecule	Approval	EMA Human Drugs	8	7	7	Drugs and targets
FEDRATINIB HYDROCHLORIDE	CHEMBL4297216	Small molecule	Approval	FDA	1	0	0	Drugs and targets
MOMELOTINIB DIHYDROCHLORIDE	CHEMBL2219411	Small molecule	Approval	FDA	1	0	0	Drugs and targets
PACRITINIB CITRATE	CHEMBL5095049	Small molecule	Approval	FDA	1	0	0	Drugs and targets
RUXOLITINIB PHOSPHATE	CHEMBL1795071	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
MOMELOTINIB	CHEMBL1078178	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PACRITINIB	CHEMBL2035187	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ROPEGINTERFERON ALFA-2B	CHEMBL4297819	Protein	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
PEGINTERFERON ALFA-2A	CHEMBL1201560	Protein	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets

1 to 10 of 63

See all 63 drugs

Targets87

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK2	Tyrosine-protein kinase JAK2	10	Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	5	Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	5	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	4	Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ABL1	Bcr/Abl fusion protein	3	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
ACVR1	Activin receptor type-1	3	Activin receptor type-1 inhibitor	Approval	https://conductscience.org/library/genes/90	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets

1 to 10 of 87

See all 87 targets

Trials65

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01969838	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis	Phase 3	432	2023-05-12	Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis	MOMELOTINIB, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT01773187	Pacritinib Versus Best Available Therapy to Treat Myelofibrosis	Phase 3	327	2020-09-29	Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	PACRITINIB	Its record names the disease	ClinicalTrials.gov
NCT02055781	Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia	Phase 3	311	2021-11-18	Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	PACRITINIB	Its record names the disease	ClinicalTrials.gov
NCT00952289	COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial	Phase 3	309	2012-01-24	MPN (Myeloproliferative Neoplasms)	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00934544	Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial	Phase 3	219	2012-05-30	Myelofibrosis	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT03952039	An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib	Phase 3	202	2024-01-30	Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis	FEDRATINIB	Its record names the disease	ClinicalTrials.gov
NCT04173494	A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)	Phase 3	195	2022-12-22	Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	DANAZOL, MOMELOTINIB	Its record names the disease	ClinicalTrials.gov
NCT02101268	Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF	Phase 3	156	2023-05-23	Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	MOMELOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00509899	Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis	Phase 1/2	154	2012-08-02	Myelofibrosis, Polycythemia Vera, Thrombocytosis	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00463385	A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia	Phase 2	88	2013-10-28	Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis	POMALIDOMIDE, PREDNISONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 65

See all 65 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pacritinib vs Best Available Therapy: Spleen Volume Reduction	42 of 220	5 of 107	327	NCT01773187	Trial comparisons
Pacritinib vs Best Available Therapy: deaths from any cause	27 of 220	3 of 106	326	NCT01773187	Trial comparisons
Pacritinib vs Best Available Therapy: serious adverse events	117 of 220	33 of 106	326	NCT01773187	Trial comparisons
Ruxolitinib vs Placebo: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24	65 of 155	1 of 153	308	NCT00952289	Trial comparisons
Ruxolitinib vs Placebo: serious adverse events	43 of 155	53 of 151	306	NCT00952289	Trial comparisons
Ruxolitinib vs Placebo: Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24	68 of 148	8 of 152	300	NCT00952289	Trial comparisons
Pacritinib vs Best Available Therapy: Total Symptom Score (TSS) Reduction	19 of 100	5 of 48	148	NCT01773187	Trial comparisons
MMB 200 mg QD + Placebo vs DAN 300 mg BID + Placebo: Number of Baseline TD Participants With TI Status at Week 24	9 of 63	3 of 34	97	NCT04173494	Trial comparisons
Treatment Arm vs Observation Arm: deaths from any cause	0 of 5	0 of 3	8	NCT01758588	Trial comparisons
Treatment Arm vs Observation Arm: serious adverse events	2 of 5	0 of 3	8	NCT01758588	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials60

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30409796	RESULT	1	PubMed
25616577	RESULT	1	PubMed
24038026	RESULT	1	PubMed
23701016	RESULT	1	PubMed
22718840	RESULT	1	PubMed
22375971	RESULT	1	PubMed
20843246	RESULT	1	PubMed
18451242	RESULT	1	PubMed
42855460	DERIVED	1	PubMed
42751490	DERIVED	1	PubMed

1 to 10 of 60

See all 60 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0009692

GET https://conductscience.org/api/diseases/v1/MONDO_0009692/drugs?page=2

API reference For AI assistants